Edgestream Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Edgestream Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$424K	Buy	+1,122	New	+$392K	0.01%	789
2024 Q2	–	Sell	-898	Closed	-$311K	–	851
2024 Q1	$311K	Sell	898 -8,134	-90%	-$2.67M	0.02%	719
2023 Q4	$2.92M	Buy	9,032 +3,754	+71%	+$1.18M	0.21%	144
2023 Q3	$1.89M	Buy	+5,278	New	+$2.04M	0.15%	209
2023 Q2	–	Sell	-762	Closed	-$365K	–	723
2023 Q1	$365K	Buy	+762	New	+$357K	0.04%	447
2022 Q4	–	Sell	-8,660	Closed	-$3.61M	–	509
2022 Q3	$3.61M	Buy	8,660 +6,857	+380%	+$3.42M	0.28%	129
2022 Q2	$892K	Buy	+1,803	New	+$939K	0.07%	343
2021 Q3	–	Sell	-499	Closed	-$322K	–	493
2021 Q2	$322K	Sell	499 -7,526	-94%	-$4.58M	0.02%	388
2021 Q1	$4.58M	Buy	+8,025	New	+$4.75M	0.26%	149

Other funds holding BIO

First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Edgestream Partners's BIO Position: Q3 2026 in Review

Edgestream Partners opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 1,122 shares worth $424K. The stake represents 0.01% of the portfolio and ranks #789 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in BIO as recently as Q1 2024.

Edgestream Partners first reported a position in BIO in Q1 2021 and has held it in 9 quarters since. The position peaked at $4.58M in Q1 2021. 311 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

Edgestream Partners held 1,122 shares of Bio-Rad Laboratories Class A worth $424K as of Q3 2026.
Bio-Rad Laboratories Class A was a new Edgestream Partners position in Q3 2026.
Bio-Rad Laboratories Class A made up 0.01% of Edgestream Partners's portfolio in Q3 2026, its #789 holding.
Edgestream Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and has held it in 9 quarters since.
Edgestream Partners's Bio-Rad Laboratories Class A position peaked at $4.58M in Q1 2021.
311 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Edgestream Partners's 13F filing for Q3 2026, filed 10 Nov 2026.